Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) hit a new 52-week high on Thursday . The stock traded as high as $23.52 and last traded at $23.00, with a volume of 50870 shares changing hands. The stock had previously closed at $23.04.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a research note on Thursday, March 27th. They set an “overweight” rating for the company.
Check Out Our Latest Research Report on AAPG
Ascentage Pharma Group International Stock Down 0.2 %
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- The Risks of Owning Bonds
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Invest in Insurance Companies: A Guide
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
